Ascendis Pharma (ASND) Misses Q1 EPS by 11c
Tweet
Share
E-mailGet Alerts ASND Hot Sheet
Join SI Premium – FREE
Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of (EUR1.58), EUR0.11 worse than the analyst estimate of (EUR1.47). Revenue for the quarter came in at EUR100.95 million versus the consensus estimate of EUR93.49 million.
For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Ascendis Pharma (ASND) PT Raised to $290 at RBC Capital
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
